248 related articles for article (PubMed ID: 19403868)
1. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin.
Matveyenko AV; Dry S; Cox HI; Moshtaghian A; Gurlo T; Galasso R; Butler AE; Butler PC
Diabetes; 2009 Jul; 58(7):1604-15. PubMed ID: 19403868
[TBL] [Abstract][Full Text] [Related]
2. One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
Aston-Mourney K; Subramanian SL; Zraika S; Samarasekera T; Meier DT; Goldstein LC; Hull RL
Am J Physiol Endocrinol Metab; 2013 Aug; 305(4):E475-84. PubMed ID: 23736544
[TBL] [Abstract][Full Text] [Related]
3. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
4. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
[TBL] [Abstract][Full Text] [Related]
5. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
6. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
7. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.
Lim S; An JH; Shin H; Khang AR; Lee Y; Ahn HY; Yoon JW; Kang SM; Choi SH; Cho YM; Park KS; Jang HC
Clin Endocrinol (Oxf); 2012 Aug; 77(2):215-23. PubMed ID: 21955147
[TBL] [Abstract][Full Text] [Related]
8. Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.
Han SJ; Choi SE; Kang Y; Jung JG; Yi SA; Kim HJ; Lee KW; Kim DJ
Diabetes Res Clin Pract; 2011 May; 92(2):213-22. PubMed ID: 21345512
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
10. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
11. Sitagliptin and metformin--novel combination therapy.
Seyoum B
Expert Opin Pharmacother; 2011 Mar; 12(4):641-6. PubMed ID: 21291346
[TBL] [Abstract][Full Text] [Related]
12. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes.
Butler AE; Jang J; Gurlo T; Carty MD; Soeller WC; Butler PC
Diabetes; 2004 Jun; 53(6):1509-16. PubMed ID: 15161755
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.
Karasik A; Aschner P; Katzeff H; Davies MJ; Stein PP
Curr Med Res Opin; 2008 Feb; 24(2):489-96. PubMed ID: 18182122
[TBL] [Abstract][Full Text] [Related]
14. Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes.
Matveyenko AV; Butler PC
Diabetes; 2006 Jul; 55(7):2106-14. PubMed ID: 16804082
[TBL] [Abstract][Full Text] [Related]
15. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
Gagliardino JJ; Santoro S; Arellano S; Di Girolamo G
Expert Opin Pharmacother; 2008 Jun; 9(9):1495-507. PubMed ID: 18518780
[TBL] [Abstract][Full Text] [Related]
16. [Effects of Metformin and Sitagliptin on islet cell function in insulin-resistant prediabetic KKay mice].
Li P; Liang LL; Wang Y; Hou D; Yang X; Yang B
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2021 Nov; 37(6):644-649. PubMed ID: 34821099
[No Abstract] [Full Text] [Related]
17. Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.
Picatoste B; Ramírez E; Caro-Vadillo A; Iborra C; Ares-Carrasco S; Egido J; Tuñón J; Lorenzo O
PLoS One; 2013; 8(10):e78330. PubMed ID: 24302978
[TBL] [Abstract][Full Text] [Related]
18. Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
van Genugten RE; van Raalte DH; Muskiet MH; Heymans MW; Pouwels PJ; Ouwens DM; Mari A; Diamant M
Eur J Endocrinol; 2014 Mar; 170(3):429-39. PubMed ID: 24297090
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Choy M; Lam S
Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin: results from clinical practice.
Maffioli P; Derosa G
Curr Med Res Opin; 2013 Nov; 29(11):1483-5. PubMed ID: 23971498
[No Abstract] [Full Text] [Related]
[Next] [New Search]
